Select Page

South Delhi Pharma, New Delhi, India

TRIKAFTA tablets. FDA-Approved. To treat cystic fibrosis (CF)

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email query@southdelhipharma.com to discuss.

TRIKAFTA is a prescription medicine. TRIKAFTA is used to treat cystic fibrosis (CF).
INDICATIONS AND USAGE
TRIKAFTA is a combination of ivacaftor, a CFTR potentiator, tezacaftor, and elexacaftor indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the CFTR gene. If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one F508del mutation.
DOSAGE FORMS & STRENGTHS

  • Tablets: fixed dose combination containing elexacaftor 100 mg, tezacaftor 50 mg and ivacaftor 75 mg.
    Co-packaged with: • Tablets: ivacaftor 150 mg.

Manufactured By: Vertex Pharmaceuticals Incorporated
Prescribing Information URL: Click Here

South Delhi Pharma facilitate the supply of “TRIKAFTA FDA Approved” medication. Supplied under Named Patient Program to all locations in India and other part of countries. Anti-Cancer drugs is available upon request after fulfilling the legal requirement (if applicable). To get best price share your mobile number and email ID.

Category:

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

1 + 6 =

Elexacaftor/tezacaftor/ivacaftor, sold under the brand name Trikafta, is a fixed-dose combination medication used in those that have cystic fibrosis with a f508del mutation. It is made up of a combination of elexacaftor, tezacaftor, and ivacaftor.

It was approved for medical use in the United States in 2019.

In June 2020, the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) recommended the approval of elexacaftor/tezacaftor/ivacaftor (Kaftrio) for the treatment of cystic fibrosis. It was approved for medical use in the European Union in August 2020.